PROVIDER RESOURCES

MORE INFORMATION. MORE SURVIVORS.

The Lung Cancer Awareness Month Coalition (LCAMC) is composed of more than 30 global non-profits focused on thoracic cancers, led by the International Association for the Study of Lung Cancer (IASLC). During Lung Cancer Awareness Month (LCAM) in November, the Coalition unites to focus on improving outcomes for lung cancer patients by educating physicians and patients on potentially lifesaving treatment options. It also works to generate more awareness among the public about the impact of lung cancer and how we can collectively battle against the disease, which is the most deadly cancer.

Screening & Early Detection Resources

Lung cancer is the leading cause of cancer-related death in the US. With your help, we can significantly improve outcomes for patients with lung cancer. Research shows that if a patient’s lung cancer is detected at an earlier stage, their 5-year survival rate can increase from as little as 4% to 55%, based on stage 1 versus stage 4 (Source: American Lung Association).

Screening for Lung Cancer – What Clinicians Need to Know – IASLC On Demand Webinar

USPSTF Guide – Talking With Your Patients About Screening for Lung Cancer

ALA Lung Force – Should My Patient Be Screened

The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency in Journal of Thoracic Oncology – Open Access Article

 Resources on Tumor Testing & Precision Medicine

Ensuring appropriate tumor testing can help you identify options for targeted therapies. Test your patients for genomic alterations and use approved biomarker tests to identify patients eligible for newer precision medicine treatments. Treating eligible patients with targeted therapies has shown to be effective.

NSCLC Pathology and Molecular Testing – What Should Clinicians Know? – On Demand Webinar

CAP/IASLC/AMP Molecular Testing Guideline

IASLC Atlas of EGFR Testing in Lung Cancer

IASLC Atlas of PD-L1 Testing in Lung Cancer

IASLC Atlas of ALK and ROS1 Testing in Lung Cancer

Molecular Testing in the Community Setting – Resources & Tools for the Multidisciplinary Team – ACCC Website

Testing and Treating ALK+ Non-Small Cell Lung Cancer – ACCC Website

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens in Journal of Thoracic Oncology – Open Access Article

 Clinical Trial Resources

For some patients, traditional chemotherapy, available targeted therapies, or radiation may not be the best option. However, clinical trials may be a good alternative. Clinical trials are an option for any patient with cancer per the National Comprehensive Cancer Network’s guidelines. Exciting new research studies may provide improved outcomes for patients with lung cancer. Considering options for clinical trials in initial treatment discussions can help ensure that patients are not excluded from any trials based on previous treatments. Enrollment in clinical trials tends to be low and patients who are not offered an appropriate trial may be missing the opportunity to receive cutting-edge treatment and excellent care.

Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity in Journal of Thoracic Oncology – Open Access Article

Optimal Care Coordination Model for Lung Cancer Patients on Medicaid – ACCC Website

LungMATCH – LCA Website

© 2017 by SQUAWKDOG